Literature DB >> 16571096

New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.

S Dvoráková1, E Václavíková, V Sýkorová, J Dusková, P Vlcek, A Ryska, Z Novák, B Bendlová.   

Abstract

Medullary thyroid carcinoma (MTC) occurs mostly as a sporadic tumor or in connection with inherited cancer syndromes-multiple endocrine neoplasia (MEN) types 2A and 2B and familial MTC. Germline mutations in the RET proto-oncogene are found in most of the familial cases. Somatic mutations in the RET proto-oncogene are detected in 23%-69% of patients with sporadic MTC. The most frequent somatic mutation is Met918Thr in exon 16 and only a small percentage of mutations in other RET exons have been observed. In a very few cases double mutations were found. Genetic screening for somatic mutations in RET exons 10, 11, 13, 14, 15, and 16 in Czech patients with sporadic MTC was carried out by DNA sequencing. This study presents a new triplesomatic mutation Gly911Asp, Met918Thr, and Glu921Lys in exon 16 of the RET proto-oncogene detected in an 18-year-old Czech male patient. In the second case, a new double-somatic mutation Val591Ile in exon 10 with a concomitant somatic mutation Met918Thr in exon 16 was found in a 77-year-old Czech female patient. These both newly described somatic multiple mutations were revealed in a hemizygous status, the loss of heterozygosity in tumor tissues in comparison with germline DNA was confirmed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16571096     DOI: 10.1089/thy.2006.16.311

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  7 in total

Review 1.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

2.  Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies.

Authors:  Karen Gómez; Jeena Varghese; Camilo Jiménez
Journal:  J Thyroid Res       Date:  2011-05-16

3.  Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.

Authors:  Mehdi Hedayati; Marjan Zarif Yeganeh; Sara Sheikhol Eslami; Shekoofe Rezghi Barez; Laleh Hoghooghi Rad; Fereidoun Azizi
Journal:  J Thyroid Res       Date:  2011-06-13

4.  Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

Authors:  M M Moura; B M Cavaco; A E Pinto; R Domingues; J R Santos; M O Cid; M J Bugalho; V Leite
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

Review 5.  Targeted Therapy for Medullary Thyroid Cancer: A Review.

Authors:  S R Priya; Chandra Shekhar Dravid; Raghunadharao Digumarti; Mitali Dandekar
Journal:  Front Oncol       Date:  2017-10-06       Impact factor: 6.244

6.  RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.

Authors:  Cristina Romei; Raffaele Ciampi; Francesca Casella; Alessia Tacito; Liborio Torregrossa; Clara Ugolini; Fulvio Basolo; Gabriele Materazzi; Paolo Vitti; Rossella Elisei
Journal:  Oncotarget       Date:  2018-01-04

7.  Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET.

Authors:  Margarita Raygada; Mark Raffeld; Andrew Bernstein; Markku Miettinen; John Glod; Marybeth S Hughes; Karlyne Reilly; Brigitte Widemann; Jaydira Del Rivero
Journal:  Am J Med Genet A       Date:  2021-02-21       Impact factor: 2.802

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.